Valuation: ImmunityBio, Inc.

Market Cap 8.79B 7.87B 7.24B 6.56B 12.26B 834B 12.49B 86.31B 34.65B 439B 32.97B 32.27B 1,384B P/E 2026 *
-8.68x
P/E 2027 * -66.3x
Enterprise Value 8.79B 7.87B 7.24B 6.56B 12.26B 834B 12.49B 86.31B 34.65B 439B 32.97B 32.27B 1,384B EV / Sales 2026 *
38.8x
EV / Sales 2027 * 18.6x
Free-Float
37.84%
Yield 2026 *
-
Yield 2027 * -
10-21 Immunitybio Announces Completion of Database Lock for Cohort A of QUILT-2.005 Trial Evaluating Anktiva Plus Bcg in Bcg-Naïve Non-Muscle Invasive Bladder Cancer CI
10-16 ImmunityBio, Inc. Reports Long-Term Data From The Phase 2/3 QUILT-3.032 Study Evaluating ANKTIVA Plus BCG In BCG-Unresponsive NMIBC With CIS, With Or Without Papillary Disease CI
10-14 FDA Expands Indication for ImmunityBio's Bladder Cancer Drug DJ
10-14 ImmunityBio, Inc. Announces FDA Expands ANKTIVA Approval For BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer To Cover Both Papillary And CIS Disease CI
10-14 ImmunityBio's Anktiva Receives FDA Approval for Expanded Indication MT
08-10 ImmunityBio, Inc. Announces Appointment of Dr. Jim Yong Kim as Vice Chairman CI
08-04 ImmunityBio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
08-04 ImmunityBio Q2 Net Loss Widens, Revenue Rises MT
08-04 Earnings Flash (IBRX) ImmunityBio Posts Q2 Net Loss $0.22 a Share, vs. FactSet Est of $0.08 Loss MT
08-04 Earnings Flash (IBRX) ImmunityBio, Inc. Reports Q2 Revenue $51.2M, vs. FactSet Est of $49.7M MT
07-30 ImmunityBio Says Anktiva Receives UAE Marketing Authorization for Certain Bladder, Lung Cancers MT
07-30 ImmunityBio Receives United Arab Emirates Marketing Authorization For ANKTIVA Across BCG-Unresponsive Non-Muscle Invasive Bladder Cancer And Metastatic Non-Small Cell Lung Cancer CI
07-07 ImmunityBio Insider Sold Shares Worth $1,246,941, According to a Recent SEC Filing MT
1 day-5.15%
1 week+0.85%
1 month-10.67%
3 months+15.62%
6 months+16.60%
Current year+318.69%
1 week 7.76
Extreme 7.765
8.94
1 month 7.75
Extreme 7.75
10.81
Current year 1.98
Extreme 1.98
12.43
1 year 1.95
Extreme 1.95
12.43
3 years 1.83
Extreme 1.83
12.43
5 years 1.21
Extreme 1.21
12.43
10 years 1.21
Extreme 1.21
40.83
Manager TitleAgeSince
Chief Executive Officer 57 2020-09-30
Chief Executive Officer 74 2015-02-28
Director of Finance/CFO 48 2021-02-28
Director TitleAgeSince
Director/Board Member 80 2021-01-31
Director/Board Member 71 2021-02-28
Chairman 74 2014-11-30
Date Insider Type Main position Quantity % Market Cap. Importance
10/5/26 Sell

Director

-25,000 0.0024%
10/2/26 Exercice

Director

193,014 0.0182%
7/2/26 Exercice

Director

243,168 0.0232%
Change 5-day change 1-year change 3-year change Capi.($)
-5.15%+0.85%+245.42%+155.08% 8.79B
-0.62%-1.87%+42.87%+67.17% 63.77B
+0.35%+3.20%+14.40%+73.89% 56.37B
+0.53%+1.96%+16.24%+102.20% 54.62B
-2.81%-4.31%+23.50%+48.51% 44.06B
-0.33%-1.93%+19.28%+104.26% 42.11B
+0.55%+2.31%+225.14%+840.10% 41B
+3.27%+47.96%+112.84%+91.02% 34.92B
+1.22%-1.44%+14.57%+47.05% 32.82B
+0.89%+20.55%-40.62%+350.50% 24.7B
Average -0.21%+6.87%+67.36%+187.98% 40.31B
Weighted average by Cap. +0.06%+5.34%+52.29%+173.01%

Financials

2026 *2027 *
Net sales 227M 203M 187M 169M 316M 21.51B 322M 2.23B 893M 11.32B 850M 832M 35.69B 472M 423M 389M 352M 658M 44.81B 671M 4.64B 1.86B 23.57B 1.77B 1.73B 74.33B
Net income -1B -899M -827M -749M -1.4B -95.26B -1.43B -9.86B -3.96B -50.11B -3.77B -3.69B -158B -122M -109M -100M -90.84M -170M -11.56B -173M -1.2B -480M -6.08B -457M -447M -19.17B
Net Debt - -
Projected Income Statement - Annual - ImmunityBio, Inc.
Logo ImmunityBio, Inc.
ImmunityBio, Inc. is a biotechnology company focused on developing and commercializing immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the goal of restoring immune function and generating lasting immunological memory in patients. The Cancer BioShield platform is designed to stimulate critical lymphocytes, including natural killer (NK) cells, cytotoxic T cells, and memory T cells via its IL-15 receptor agonist, ANKTIVA. The Cancer BioShield platform is anchored by this antibody-cytokine fusion protein and is complemented by a portfolio that includes adenovirus-vectored vaccines, allogeneic (off-the-shelf) and autologous NK-cell therapies, and additional immunomodulators intended to promote immunogenic cell death and support durable immune responses while potentially reducing reliance on high-dose chemo-radiation therapy.
Employees
688
Date Price Change Volume
26-10-30 US$8.290 -5.15% 8,960,344
26-10-29 US$8.740 -0.79% 7,148,335
26-10-28 US$8.810 +2.09% 7,166,194
26-10-27 US$8.630 +10.50% 10,508,797
26-10-26 US$7.810 -4.99% 11,049,307
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
MarketScreener Ratings - ImmunityBio, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
8.290USD
Average target price
14.25USD
Spread / Average Target
+71.89%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - ImmunityBio, Inc.
  1. Stock Market
  2. Stocks
  3. IBRX Stock